Autologous tumor-infiltrating lymphocytes

BIOLOGICAL4 trials

Sponsors

Inge Marie Svane, Women's Hospital School Of Medicine Zhejiang University, Beijing 302 Hospital, Yong Wha Moon

Conditions

CancerHepatocellular CarcinomaRecurrent Ovarian CancerTumor Infiltrating Lymphocytes

Phase 1

Adoptive Cell Therapy Across Cancer Diagnoses

CompletedNCT03296137

Inge Marie SvaneCancer

Start: 2017-10-13End: 2020-07-01Updated: 2024-10-26

Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer

Not yet recruitingNCT05152797

Women's Hospital School Of Medicine Zhejiang UniversityTumor Infiltrating Lymphocytes

Start: 2022-01-01End: 2026-12-31Target: 91Updated: 2021-12-10

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

RecruitingNCT06463522

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-07-01End: 2026-07-01Target: 20Updated: 2024-08-13

Unknown Phase

To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

RecruitingNCT07651124

Yong Wha MoonRecurrent Ovarian Cancer

Start: 2025-04-01End: 2027-06-30Target: 6Updated: 2026-06-16

Related Papers

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Journal for ImmunoTherapy of Cancer2023-05-0131 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations